A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of this study is to evaluate and compare the safety and efficacy of two drugs (ADVAGRAF® and PROGRAF® groups) in patients who received renal transplantation.
Epistemonikos ID: 9ff013049b1bdf2cba22377f577cfa762c00a24b
First added on: May 11, 2024